{"name":"Polpharma","slug":"polpharma","ticker":"Private","exchange":"N/A","domain":"polpharma.pl","description":"Polpharma is a private Polish pharmaceutical company specializing in the development and manufacturing of generic and biosimilar medicines. The company focuses on therapeutic areas such as oncology, immunology, and cardiovascular diseases. With a strong presence in the European market, Polpharma aims to expand its global reach through strategic partnerships and investments. As a leading player in the generics and biosimilars sector, Polpharma continues to innovate and improve access to affordable medicines worldwide.","hq":"Starogard Gdanski, Poland","founded":0,"employees":"","ceo":"Markus Sieger","sector":"Generics / Biosimilars","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":1500000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Letrozole patent cliff ($1.2B at risk)","drug":"Letrozole","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Pemetrexed patent cliff ($800M at risk)","drug":"Pemetrexed","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Intravenous (IV) infusions","genericName":"Intravenous (IV) infusions","slug":"intravenous-iv-infusions","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Intravenous (IV) infusions","genericName":"Intravenous (IV) infusions","slug":"intravenous-iv-infusions","phase":"phase_3","mechanism":"IV infusions are a delivery route for pharmaceutical agents administered directly into the bloodstream.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"deal","headline":"Polpharma Acquires Polish Pharmaceutical Company","summary":"Polpharma has acquired a Polish pharmaceutical company, expanding its portfolio of generic and biosimilar medicines.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"Polpharma Receives FDA Approval for Generic Version of Cancer Medication","summary":"The US FDA has approved Polpharma's generic version of a widely used cancer medication, further solidifying the company's presence in the US market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"pipeline","source":"Новости GxP","summary":"One of Poland’s wealthiest businessmen to build a pharmaceutical plant in Kazakhstan for nearly 40 bln tenge - Новости GxP","headline":"One of Poland’s wealthiest businessmen to build a pharmaceutical plant in Kazakhstan for nearly 40 bln tenge - Новости G","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOVV91SlpBOE9vcG82UUxHTmVLdjdyeHBYdXNPTF9hNjBQZ3c1Q05QR1EtMGZaYi1EMDN2c0tERDJTZEJnX3cyZEhrM1Z5NWZzNEQ5RWVma0JINFJtN3VrbWpMb2d4UG5uUEotbkVZNC1zTDZDQkpwakZ5bWkyY1Y4V3JUY3BqcmxQbE9BUC1USWVyZFZ5TnhlS0Z5N2FyUnpLOWFRelgzUmhOODNyanVPNFczcW1DWVFwUV9hVTBsUlBGMkNuMlhYa1lIajZYOUU?oc=5","date":"2025-09-11","type":"patent","source":"Reuters","summary":"Private equity firm Advent to sell generic drugmaker Zentiva to GTCR - Reuters","headline":"Private equity firm Advent to sell generic drugmaker Zentiva to GTCR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxNeE5iaGMyQi1oVnJYbmZrVW5zUFV2YldLSGdCTVVBX0trRjZUUFdpbkljSHRSX3lWTjZqcDZLdHZzNW4ycUkzZlVHd3RKNFFnbFE4cXg3NEltMnF1OHEtZmRIR3BoUjJUY1FYOFJXZWJnRnQ2YTlOYlM0Z2d4UHZUb0RSYWFJcTZBVUhoTWd3cXRDMHVwYjh6SXBkLXdIWFNnamVkNXpZYlpnS1NEQ0RXVUNNcTBveDloMkxyS0xaR1d5SWdpZmR4YUZSbG15b245V01paHdBX2NRTm4xQ0RHZ19UVHpxU08zZ19iTUFMNDVaaXBoZnpPZ05aMzlYdVByLWU1RQ?oc=5","date":"2025-09-03","type":"patent","source":"Business Wire India","summary":"Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars - Business Wire India","headline":"Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Gu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZDlDbDRNbXVMTmdkdVNQaW5KbzdPMjN6Q0plVUJnVXVVOXIxd3pQQkd2WjNVcUZBRWMwN3JhSXVuN0ZydzF3Z0ZnMi1JZDVDUk5wTDhseDRxZDNfX1NTY0huQ2loSlQxOVBzT3d5Y0o3WlBOMERBZlN4cjk0Ym9uM1pYNFpmaVpteDNHRXpXUUVNbkNJcmtjSUJyd0RvUzdPTktLN3AxcFJFUQ?oc=5","date":"2025-08-06","type":"deal","source":"Pharmaceutical Technology","summary":"Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar - Pharmaceutical Technology","headline":"Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOWWhKazJUcDQwdEc0WEJfTlZ0a0lOR1lvOWs5WW9ZUGx5ajZxUUlxcnFnNXIzbGdkNTl6MzBxajVwMG5WWXJGZG5DY3pWR0VBT1poSmtpRkpndkVTcXdtY2NrLTVZSmpkVEREVF85WndjVkZGdm5OekVZZk8yQUFrdU9abmk2MHo5NlFkcmc2R1BQRWRQQ1ZSQXFXM0xOaU9JMnJaTjJOZDFOOW9fLXd3QVJFM0JmUQ?oc=5","date":"2022-01-21","type":"deal","source":"Fierce Pharma","summary":"Poland's largest pharma scouts for joint bidder in potential $4B buyout of former Sanofi generics unit: Reuters - Fierce Pharma","headline":"Poland's largest pharma scouts for joint bidder in potential $4B buyout of former Sanofi generics unit: Reuters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSGFGY2padktTRkJtYjZCQjVmVHZOXzh5dHNkLTlMLWsyUkhkWVJLUE15QlJQN2hfYUowYms4SUoyaVh4QlhPQ212UnlHdWw5eVZiVXpRdHFpcUpwMXY1MWRoakVXbzAwM2trc19IaVl6eGRyWkdmdVM5Zl9vcmw1YXhOY01DRXcxR2hyb3V1dHM1TWVOZlhjb3ZPWGduMmVCNjVYbV9UNlV5NDN1LWQzelhTQnFkVEsxZm5TSmo4bm9KQQ?oc=5","date":"2022-01-20","type":"pipeline","source":"Reuters","summary":"EXCLUSIVE Polish drug maker Polpharma working on bid for Advent's Zentiva - sources - Reuters","headline":"EXCLUSIVE Polish drug maker Polpharma working on bid for Advent's Zentiva - sources","sentiment":"neutral"}],"patents":[{"drugName":"Letrozole","drugSlug":"letrozole","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Pemetrexed","drugSlug":"pemetrexed","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"EU","annualRevenue":800000000}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Mylan","Teva"],"therapeuticFocus":["Oncology","Immunology","Cardiovascular Diseases"],"financials":null,"yahoo":null}